GHRS Stock Rallies 55% in a Week: Here's What You Should Know

Shares of GH Research PLC (GHRS) have rallied 54.8% in a week after the company, on Feb. 3, 2025, announced that it has met the primary goal in a mid-stage study of its investigational, inhalable mebufotenin product candidate, GH001, to treat patients with treatment-resistant depression (TRD).Per the data readout from the phase IIb TRD study, 40 patients treated with GH001 achieved a significant 15.2-point reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) score by Day 8, while the placebo group ...